Engineered platelets-based drug delivery platform for targeted thrombolysis

Engineered platelets-based drug delivery platform for targeted thrombolysis

Thrombolytic agents have thus far yielded limited therapeutic benefits in the treatment of thrombotic disease due to their short half-life, low targeting ability, and association with serious adverse reactions, such as bleeding complications. Inspired by the natural roles of platelets during thrombu...

Full description

Bibliographic Details
Main Authors: Songli Wang, Ruifeng Wang, Nana Meng, Linwei Lu, Jun Wang, Jianfen Zhou, Jiasheng Lu, Qianzhu Xu, Cao Xie, Changyou Zhan, Yao Li, Yang Yu, Weiyue Lu, Min Liu
Format: Article
Language:English
Published: Elsevier 2022-04-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Platelet
Urokinase
Nitric oxide
Targeted thrombolysis
Thrombus reformation
Online Access:http://www.sciencedirect.com/science/article/pii/S221138352200017X

Internet

http://www.sciencedirect.com/science/article/pii/S221138352200017X

Similar Items